MedTrace Logo

Efficacy of Pioglitazone and Insulin in Treating Subjects With Type 2 Diabetes Mellitus and Renal Failure.

NCT00770640 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-09-01

No results posted yet for this study

Summary

The purpose of this study is to determine the metabolic and cardiovascular effects of pioglitazone, once daily (QD), and insulin combination therapy in subjects with Type 2 Diabetes and Renal Failure.

Conditions

Interventions

DRUG

Pioglitazone and insulin

Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.

DRUG

Insulin

Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda Pharma GmbH, Aachen (Germany)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770640 on ClinicalTrials.gov